Lunai Bioworks (LNAI) Payables (2011 - 2026)
Lunai Bioworks (LNAI) posted quarterly Payables of $12.7 million for Q1 2026, up 5.88% year-over-year from $12.0 million in Q1 2025, and up 2.72% quarter-over-quarter from $12.3 million in Q4 2025.
Lunai Bioworks (LNAI) Payables (2011 - 2026) Analysis & Trends
Lunai Bioworks' Payables history runs 16 years deep, the most recent figure standing at $12.7 million for Q1 2026.
- In Q1 2026, Payables rose 5.88% year-over-year to $12.7 million; the TTM figure through Mar 2026 stood at $12.7 million (up 5.88% YoY), while the FY2025 annual figure was $12.6 million, up 29.53% from the prior year.
- Payables for Q1 2026 stood at $12.7 million, up from $12.3 million in the prior quarter.
- The five-year high for Payables was $12.7 million in Q1 2026, with the low at $2.6 million in Q2 2022.
- The 5-year median for Payables is $9.9 million (2023), against an average of $9.7 million.
- The sharpest annual moves came in 2022 and 2024: Payables surged 973.76% in 2022, then dropped 2.3% in 2024.
- Lunai Bioworks' Payables stood at $9.3 million in 2022, then gained by 2.55% to $9.5 million in 2023, then gained by 17.46% to $11.2 million in 2024, then rose by 10.38% to $12.3 million in 2025, then increased by 2.72% to $12.7 million in 2026.
- Business Quant data shows LNAI's Payables at $12.7 million in Q1 2026, $12.3 million in Q4 2025, and $12.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.41 Bn | 130.56 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.41 Bn | 59.23 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 57.56 Bn | 52.43 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.06 Bn | 36.96 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.95 Bn | 27.65 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.48 Bn | 9.09 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.31 Bn | 26.15 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.04 Bn | 26.20 Bn | - | 35.57 Mn |
| 10 | Lunai Bioworks | 6.94 Mn | 3.78 Mn | 20,942.00 | 12.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.68 Mn |
| Dec 31, 2025 | 12.34 Mn |
| Sep 30, 2025 | 12.09 Mn |
| Jun 30, 2025 | 12.56 Mn |
| Mar 31, 2025 | 11.97 Mn |
| Dec 31, 2024 | 11.18 Mn |
| Sep 30, 2024 | 11.65 Mn |
| Jun 30, 2024 | 9.69 Mn |
| Mar 31, 2024 | 11.41 Mn |
| Dec 31, 2023 | 9.52 Mn |
| Sep 30, 2023 | 8.33 Mn |
| Jun 30, 2023 | 9.92 Mn |
| Mar 31, 2023 | 9.27 Mn |
| Dec 31, 2022 | 9.28 Mn |
| Sep 30, 2022 | 5.88 Mn |
| Jun 30, 2022 | 2.60 Mn |
| Mar 31, 2022 | 5.29 Mn |
| Dec 31, 2021 | 4.89 Mn |
| Sep 30, 2021 | 547,866.00 |
| Jun 30, 2021 | 320,559.00 |